Entrada Therapeutics, Inc. (TRDA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.55-10.08%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TRDA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive…
Stated in 3 of 3 supplied quarters. Management reported: ““The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.” ““With these initial dose cohorts supporting the safety profile of our lead Duchenne programs, our attention now turns to the next set of readouts designed to further define the potential of our investigational medicines.” Revenue was $0.905 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive…”
“"We are entering a catalyst-rich period with several near-term clinical data readouts including ELEVATE-45-201 Cohort 1 in October 2026, ELEVATE-44-201 Cohort 1 open-label period by year-end 2026 and…”
“Document Entrada Therapeutics Reports First Quarter 2026 Financial Results -- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, toler…”
Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into the fourth qua…
Stated in 3 of 3 supplied quarters. Management reported: “Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into the fourth quarter of 2027.” ““The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.”
“Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its operations into the fourth qua…”
“Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of June 30, 2026 will be sufficient to fund its operations into the third quarter o…”
“Based on current operating plans, the Company believes that its cash, cash equivalents and marketable securities as of March 31, 2026 will be sufficient to fund its operations into the third quarter…”
Vertex is on track to share interim results from the GALILEO study in the second half of 2026.
Stated in 3 of 3 supplied quarters. Management reported: “VX-670: Vertex has completed enrollment and dosing in the MAD portion of the GALILEO global Phase 1/2 clinical trial of VX-670 in people with DM1.” “Vertex is on track to share interim results from the GALILEO study in the second half of 2026.”
“Vertex is on track to share interim results from the GALILEO study in the second half of 2026.”
“Vertex is on track to complete dosing and report results in the second half of 2026.”
“The Company is also carefully evaluating the optimal timing for initiating the planned clinical studies of ENTR-601-50 and ENTR-601-51.””
Recent Corporate Highlights Clinical-Stage Development Pipeline: Entrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy (DMD) in the U.K., EU and U.…
Complete and report data from the Cohort 1 open-label period and Cohort 2 multiple ascending dose study of ENTR-601-44 by the end of 2026.
Over the trailing year it converted 2.55x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.